SLC2A1 and hepatocellular carcinoma: Furthermore, some drugs targeting GLUT1 have been designed, such as WZ35 (a curcumin analog), which can inhibit GLUT1 expression by suppressing YAP transcriptional activity, thereby reducing cellular glucose uptake and glycolysis to exert tumor-suppressing effects in HCC (25).